Free tool
Rare disease stocks
We cover 5 companies grouped under the Rare disease theme. The median market value in the group is $79.34M. Across the group, the median move over the past trading day is 0.00%. Price change over the past year runs from −86.6% to −18.6% across the middle 80 percent of the group, with a median of −64.2%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | $139.70B | Large cap | −83.18% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $35.05B | Large cap | −46.60% |
| TENX | Tenax Therapeutics, Inc. | $79.34M | Micro cap | −64.19% |
| CVKD | Cadrenal Therapeutics, Inc. | $4.80M | Micro cap | −88.87% |
| ANR.AX | Anatara Lifesciences Ltd | $2.05M | Micro cap | 0.00% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.